CVS Health Corporation (TSX:CVS)
Canada · Delayed Price · Currency is CAD | Market Cap | 172.69B +55.8% |
| Revenue (ttm) | 586.00B +7.4% |
| Net Income | 6.94B +7.9% |
| EPS | 5.42 +6.3% |
| Shares Out | n/a |
| PE Ratio | 24.87 |
| Forward PE | 11.75 |
| Dividend | 0.64 (2.75%) |
| Ex-Dividend Date | Jul 23, 2026 |
| Volume | 23,403 |
| Open | 22.70 |
| Previous Close | 23.08 |
| Day's Range | 22.69 - 23.02 |
| 52-Week Range | 15.35 - 26.46 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About CVS Health
CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans; medical management capabilities; Medicare Advantage and Medicare Supplement plans; prescription drug plans (PDPs); and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care prov... [Read more]
Financial Performance
In 2025, CVS Health's revenue was $399.83 billion, an increase of 7.87% compared to the previous year's $370.66 billion. Earnings were $1.77 billion, a decrease of -61.68%.
Financial numbers in USD Financial StatementsNews
Medicare Made Weight-Loss Drugs $50 A Month—Now Amazon, CVS And Walmart Race To Fill Prescriptions
More than 66 million. That's how many people in the U.S. get their health coverage from Medicare, according to the insurance program.
CVS Health price target raised to $107 from $94 at Baird
Baird analyst Michael Ha raised the firm’s price target on CVS Health (CVS) to $107 from $94 and keeps an Outperform rating on the shares.
CVS Health price target lowered to $125 from $130 at Evercore ISI
Evercore ISI lowered the firm’s price target on CVS Health (CVS) to $125 from $130 and keeps an Outperform rating on the shares.
CVS Health price target raised to $126 from $122 at UBS
UBS raised the firm’s price target on CVS Health (CVS) to $126 from $122 and keeps a Buy rating on the shares. CVS delivered a better-than-expected quarter with improving HCB…
CVS Health price target raised to $108 from $106 at Barclays
Barclays raised the firm’s price target on CVS Health (CVS) to $108 from $106 and keeps an Overweight rating on the shares post the Q2 report. The company called out…
CVS Stock Drops 6% as Early 2027 Warnings Shadow Strong $2.9 Billion Profit Beat
CVS Health shares ($CVS) fell about 6% on Wednesday despite net income nearly tripling to $2.98 billion, or $2.31 per share, for the second quarter. Investors focused on future customer…
CVS Health says ‘encouraged by the momentum we’re seeing’
Says continuing to implement technology enhancements. Says embedding AI into the company’s processes. Says maintaining “disciplined approach” to costs, price actions. Comments taken from Q2 earnings c...
CVS Health seeing ‘pockets of favorability’ in Medicare business
Says leverage ratio was 3.5x at end of Q2 and expects further improvement by year end. Says will continue to evaluate capital deployment strategies. Expects 2H EPS “weighted towards Q3.”…
CVS Health says FY27 EPS of at least $8.44 ‘seems reasonable’
FY27 EPS consensus $8.43.
CVS Health Earnings Call Transcript: Q2 2026
Q2 2026 saw broad-based revenue and earnings growth, with adjusted EPS up 40% and all segments outperforming. Full-year guidance was raised for EPS and cash flow, driven by strong pharmacy, health services, and benefits results, despite ongoing 340B and reimbursement headwinds.
CVS Health Quarterly report: Q2 2026
CVS Health has published its Q2 2026 quarterly earnings report on August 5, 2026.
CVS Health Slides: Q2 2026
CVS Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
CVS Health Earnings release: Q2 2026
CVS Health released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
CVS Health raises FY26 revenue ‘at least’ $414B, consensus $409.48B
Prior view was ‘at least’ $405B. Raises FY26 consolidated adjusted operating income view to $16.58B-$16.92B from $15.53B-$15.87B. Guidance taken from investor presentation slides.
CVS Health announces revamp of weight management program
CVS Health (CVS) announced a revamp of its weight management program, making it easier for eligible adults to access clinical care, navigate medication costs and get ongoing support for GLP-1…
CVS Health Profits Hit $2.9 Billion As Firm Gets Handle On Aetna Costs
CVS Health Wednesday reported second quarter net income nearly tripled to $2.9 billion compared to the year-ago quarter as the company gets a better handle on rising costs in its Aetna health plans.
CVS Health raises FY26 adjusted EPS view to $7.90-$8.10 from $7.30-$7.50
Consensus $7.45. Raises FY26 cash flow from operations view to at least $11.5B from at least $9.5B. The company said, “The Company is increasing its full-year 2026 GAAP diluted EPS,…
CVS Health Launches Eli Lilly GLP-1 Partnership, Lifts Outlook as Profit Increases
CVS Health said it will revamp its weight management program through a partnership with Eli Lilly as the company lifted its full-year outlook and reported a nearly threefold increase in its second-qua...
CVS Health reports Q2 adjusted EPS $2.58, consensus $1.85
Reports Q2 revenue $106.1B, consensus $100.09B. “Our CVS Health (CVS) colleagues build trust every day in communities across our country by making healthcare easier for millions of customers, patients...
CVS raises annual profit forecast on improved drug revenues
CVS Health on Wednesday raised its annual profit forecast to reflect a better-than-expected second quarter marked by a more profitable mix of drugs in its pharmacy business and bonus payments for it...
CVS blows past estimates, hikes guidance as insurance unit continues to improve
CVS Health blew past second-quarter earnings and revenue estimates and raised its 2026 guidance, as its insurance unit Aetna shows signs of recovery. All three of the healthcare giant's business segm...
CVS HEALTH CORPORATION REPORTS STRONG SECOND QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE
Second quarter total revenues increased to $106.1 billion, up 7.3% year-over-year Second quarter GAAP diluted EPS of $2.31 and Adjusted EPS of $2.58 Generated year-to-date cash flow from operations of...
CVS Health enhances its direct-to-consumer weight management offerings to improve access, affordability, care and support for GLP-1 medications
CVS Pharmacy offers all FDA approved GLP-1s, whether through insurance or cash-pay options. New collaboration with Eli Lilly and Company will provide eligible Zepbound and Foundayo patients an additio...
CVS's Turnaround Faces Its Next Test
CVS Health reports earnings Wednesday, with analysts expecting another solid quarter and looking for potential guidance upside from its Aetna insurance and Caremark pharmacy-benefit businesses.
CVS Health earns two Gold and one Silver Stevie® Awards for Great Employers
AI Learning Academy honored for building enterprise-wide AI literacy and colleague confidence WOONSOCKET, R.I., Aug. 4, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that its AI Learnin...